Companies: 10,795·Total market cap: $144.5T
KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.

KALVNASDAQHealthcare● Active
$26.99
+$0.04(+0.13%)
Market Cap$1.4B
P/E Ratio
52W High$26.99
52W Low$9.83

KalVista Pharmaceuticals, Inc. (KALV) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

KALV · shares outstanding · updated Jun 8, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
50.9M +2.51% YoY Change
FY · as of Dec 31, 2025 · Reported in USD
vs 49.7M in FY 2025
Diluted Shares Outstanding
50.9M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
+2.51%
year-over-year
Float (Free Float)
38.2M
publicly tradable shares
71.7% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-08

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+22.2%
2023 → 2025
5-Year CAGRincreasing
+21.7%
2021 → 2025
10-Year CAGRincreasing
+26.7%
2016 → 2025

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2025Latest
Diluted Shares: 50.9M
50.9M
+2.51%
FY 2025
Diluted Shares: 49.7M
49.7M
+34.98%
FY 2024
Diluted Shares: 36.8M
36.8M
+31.89%
FY 2023
Diluted Shares: 27.9M
27.9M
+13.97%
FY 2022
Diluted Shares: 24.5M
24.5M
+28.17%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs KALV
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
KalVista Pharmaceuticals, Inc.KALV
KalVista Pharmaceuticals, Inc.YOU
50.9M

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

KalVista Pharmaceuticals, Inc. (KALV) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, KalVista Pharmaceuticals, Inc. reports 50.9M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

KalVista Pharmaceuticals, Inc.'s basic shares outstanding (50.9M) represents currently issued shares. Diluted shares outstanding (50.9M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

KalVista Pharmaceuticals, Inc.'s float is 38.2M (71.7% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float38.2M(71.7%)
Outstanding53.2M

Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

KalVista Pharmaceuticals, Inc. (KALV) shares outstanding history from 2012 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

KalVista Pharmaceuticals, Inc. shares outstanding for the fiscal year ending December 31, 2025 were 50.9M, a 2.51% increase year-over-year. KalVista Pharmaceuticals, Inc. FY 2025 shares outstanding were 50.9M, a +2.51% increase from FY 2025.

KalVista Pharmaceuticals, Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of +26.7% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.

Frequently asked questions

KALV shares outstanding · 4 questions

As of December 31, 2025, KalVista Pharmaceuticals, Inc. (KALV) has approximately 50.9M basic shares outstanding and 50.9M diluted shares outstanding. This represents a +2.51% year-over-year increase from FY 2025 (49.7M). The increase may reflect equity compensation issuances or secondary offerings.

KALV shares outstandinghow many shares does KALV haveKALV basic shares 2025KALV diluted shares

Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · KalVista Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-08